Could a Liver-Stage malaria vaccine shield mothers and babies?
NCT ID NCT07675785
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new malaria vaccine (PfSPZ-LARC2) designed to stop the malaria parasite in the liver before it can cause illness. The study involves 300 healthy women of childbearing age in Mali who plan to become pregnant. Participants receive three doses of the vaccine or a placebo, and researchers monitor safety, immune response, and protection against malaria over two years, including during pregnancy and after delivery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PfSPZ-LARC2 Vaccine (live, weakened malaria parasites)
What this could lead to
If successful, this vaccine could protect women and their future babies from malaria, potentially reducing severe illness and death in high-risk areas.
What could go wrong
This is a phase 2 trial with 300 participants, so results may not apply broadly. The vaccine uses live parasites, which carries a risk of causing malaria-like symptoms or unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Sciences, Techniques and Technology, Bamako (USTTB)
Bamako, Mali
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••